Arcturus Therapeutics Holdings Inc. (ARCT) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2023
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 1, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) trades at a price-to-earnings ratio of -2.7x, with a stock price of $8.23 and trailing twelve-month earnings per share of $-2.45.
The current P/E is 112% below its 5-year average of 23.4x. Over the past five years, ARCT's P/E has ranged from a low of 5.9x to a high of 70.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ARCT trades at a 112% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, ARCT trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARCT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. RNA and Genome Editing Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | $44B | 142.9 | -Best | +207% |
SLXNWSilexion Therapeutics Ltd. | $64M | 0.0Lowest | -Best | +6436%Best |
DTILPrecision BioSciences, Inc. | $51M | 4.0 | -Best | +107% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $25.55 | $3.61 | 7.1x | -70% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $28.68 | $2.92 | 9.8x | -58% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $23.97 | $4.08 | 5.9x | -75% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $16.96 | $0.24 | 70.7x | +203% |
Average P/E for displayed period: 23.4x
See ARCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARCT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ARCT vs AGIO
See how ARCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ARCT stock overvalued or undervalued?
ARCT trades at -2.7x P/E, below its 5-year average of 23.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ARCT's valuation compare to peers?
Arcturus Therapeutics Holdings Inc. P/E of -2.7x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is ARCT's PEG ratio?
ARCT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2023.